[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Taiwan University Clinical Trial Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":184},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,76,103,132,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100639028","effects-of-combined-thoracic-and-diaphragmatic-breathing-on-cognitive-and-psycho-physiological-functions-100639028",false,"NCT07620249","Effects of Combined Thoracic and Diaphragmatic Breathing on Cognitive and Psycho-Physiological Functions","The Effects of Combined Thoracic Expansion Exercises and Slow Diaphragmatic Breathing on Cognitive Function, Brain Activation, Psychological Status, and Head-Shoulder Posture in Healthy Adults","Inclusion Criteria:\n\n1. age between 18 to 30 years with at least a high school education to ensure baseline cognitive task comprehension\n2. the ability to adhere to verbal instructions\n3. no regular participation in formal breathing exercise or mindfulness training within the past six months.\n\nExclusion Criteria:\n\n1. a history of musculoskeletal, cardiovascular, or cerebrovascular diseases which may interfere this study\n2. history of respiratory disease or recent respiratory infection\n3. diabetes mellitus with neuropathy, peripheral neuropathy, or other neurological disorders\n4. major surgery within the past six months\n5. Current or past major psychiatric disorders or cognitive impairment\n6. use of medications significantly affecting cerebral hemodynamics or autonomic function (e.g., beta-blockers, vasodilators) within the past 2 weeks\n7. use of psychotropic medications or substances known to alter cerebral blood flow, neural activation, or autonomic regulation (e.g., antidepressants, antipsychotics, anxiolytics, stimulants, or sedative-hypnotics).",true,"ALL","18 Years","30 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to investigate the effects of a combined thoracic expansion exercise (TEE) and slow diaphragmatic breathing (SDB) program on cognitive function, brain activation, psychological status, and head-shoulder posture in healthy young adults.",[28],"Diaphragm Pacing",[30,31,32,33],"breathing exercise","autonomic regulation","cognitive function","functional near-infrared spectroscopy","NOT_YET_RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":22},"2026-05-25",{"date":42,"type":22},"2027-02-01",{"name":44,"class":45},"National Taiwan University Clinical Trial Center","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100611332","serious-game-for-improving-targeted-temperature-management-knowledge-and-situational-awareness-in-critical-care-nurses-100611332","NCT07239206","Serious Game for Improving Targeted Temperature Management Knowledge and Situational Awareness in Critical Care Nurses","Effectiveness of Serious Game on Facilitating Targeted Temperature Management Knowledge and Situational Awareness Among Critical Care Nurses","Inclusion Criteria:\n\n* Registered nurses currently working in adult intensive care units (medical, surgical, or mixed ICUs).\n* Able to read and understand Chinese.\n* Willing to participate and provide informed consent.\n* Available to complete pre-test, post-test, and follow-up assessments.\n\nExclusion Criteria:\n\n* Nurses working in pediatric or neonatal ICUs.\n* Nurses holding administrative or supervisory positions (non-clinical).\n* Nurses currently participating in other TTM-related educational or research programs.\n* Individuals unable to complete the intervention or evaluation schedule.","20 Years",{"count":55,"type":22},120,[25],"This randomized controlled trial aims to evaluate the effectiveness of a serious game in improving targeted temperature management (TTM) knowledge and situational awareness among critical care nurses. A total of 120 nurses from adult intensive care units will be randomly assigned to either a control group receiving traditional lecture-based teaching or an experimental group receiving lecture-based teaching combined with a digital serious game. Outcomes will be measured using a TTM knowledge test, a situational awareness scale, and a system usability scale. The findings will provide evidence for the use of serious games as an innovative educational strategy to enhance post-resuscitation care quality and patient safety.",[59,60,61,62],"Targeted Temperature Management","Nursing Education","Serious Game","Cardiac Arrest",[64,65],"Targeted temperature management","Serious game","RECRUITING","2026-01-20",{"date":69,"type":38},"2026-01-22",{"date":71,"type":38},"2026-01-19",{"date":73,"type":22},"2026-12-31",{"name":44,"class":45},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":75},"100608519","phase-2-dcnk-cell-therapy-100608519","NCT07202611","DC\u002FNK Cell Therapy","In Vitro Culture of Autologous Dendritic and Natural Killer Cells for the Treatment of Patients With Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Eligibility of Participants:\n\n   o Diagnosed histologically or cytologically with stage IIIB or stage IV non-small cell lung cancer (NSCLC) or patients with recurrence or progression following multimodal treatments (radiotherapy, surgical resection, or therapeutic chemoradiotherapy for locally advanced disease).\n   * Have undergone at least two systemic therapies for advanced NSCLC, including platinum-based chemotherapy, anti-PD-1 therapy, and\u002For other targeted therapies.\n2. At Least One Measurable Lesion:\n\n   o The measurable lesion must not undergo radiotherapy during the cell therapy period.\n3. Age:\n\n   o ≥20 years.\n4. Weight:\n\n   o Between 40 and 100 kg.\n5. Normal Blood Count (based on test results within 4 weeks before blood collection for cell preparation):\n\n   o White blood cells (WBC): ≥3000\u002Fmm³.\n\n   o Lymphocytes: ≥1000\u002Fmm³.\n   * Hemoglobin: ≥10 g\u002FdL.\n   * Platelets: ≥100,000\u002Fmm³.\n6. Normal Liver and Kidney Function (based on test results within 4 weeks before blood collection for cell preparation):\n\n   * Creatinine: ≤1.25× the upper limit of normal (ULN).\n   * Total bilirubin: ≤1.5× ULN.\n   * SGOT (AST): ≤3× ULN.\n   * SGPT (ALT): ≤3× ULN.\n7. Informed Consent:\n\n   o Participants must sign the consent form.\n8. ECOG Performance Status:\n\n   o Score of 0-1.\n9. For Women of Childbearing Age:\n\n   * Must agree to use effective contraception during the trial.\n\nExclusion Criteria:\n\n1. Positive Test Results for the Following Infections:\n\n   o HCV (HCV antibody-positive).\n   * HBV (HBsAg-positive).\n   * HIV (HIV antibody-positive).\n   * HTLV (HTLV antibody-positive).\n   * Syphilis (Treponema pallidum antibody-positive).\n   * Tuberculosis (TB culture-positive).\n2. ECOG Performance Status:\n\n   o Score of 2-4.\n3. Albumin Intolerance:\n\n   o Participants who cannot tolerate albumin.\n4. Short Life Expectancy:\n\n   o Life expectancy estimated by the physician to be less than 12 weeks.\n5. Participation in Other Clinical Trials:\n\n   o Within 30 days prior to entering this trial.\n6. Pregnancy or Breastfeeding:\n\n   o Positive pregnancy test or currently breastfeeding.\n7. Other Medical Conditions:\n\n   o Immunodeficiency, severe heart or lung dysfunction, coagulation disorders, unresolved side effects from prior cancer therapy (not recovered to CTCAE grade 1), prior transplant surgery, or deemed unsuitable by the physician.\n8. Noncompliance:\n\n   o Unable to adhere to follow-up or examination procedures.\n9. Concurrent Cancer:\n\n   o Other cancers diagnosed within the past 2 years.\n10. Specific Complications:\n\n    * Brain metastases, leptomeningeal disease, or spinal cord compression.",{"count":84,"type":22},10,[86],"PHASE2","Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use.\n\nSecondary Outcomes\n\nTo verify the success rate of the cultured cell formulations and assess the cytotoxic capacity of natural killer cells in targeting and killing tumor cells. The evaluation of these secondary objectives involves analyzing specific subcategories, which can be divided into two major components:\n\n1. Validation of Cultured Cell Preparation Success: Assessing the proliferation rate, recovery rate, survival rate, and tumor-killing capacity of the cultured autologous dendritic cells and natural killer cells.\n2. Validation of Antitumor Effectiveness: Evaluating the antitumor efficacy of the trial products administered via axillary lymph node injection of autologous dendritic cells and intravenous infusion of autologous natural killer cells.",[89],"Lung Cancer (NSCLC)",[91,92,93,94],"lung cancer","cell therapy","NK cell","Dendritic cell","2025-09-23",{"date":97,"type":38},"2025-10-02",{"date":99,"type":38},"2022-12-02",{"date":101,"type":22},"2025-12-31",{"name":44,"class":45},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":75},"100603077","the-quality-of-life-and-viral-control-effect-of-aids-patients-after-long-acting-injection-of-cabotegravir-and-rilpivirine-100603077","NCT07131826","The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine","Inclusion Criteria:\n\n18 years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire\n\nExclusion Criteria:\n\nNot clinical diagnosis of HIV infection Do not accept questionnaires","99 Years",{"count":111,"type":22},200,"OBSERVATIONAL","\"AIDS\" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.",[115,116,117,118,119],"Viral Control","Quality of Life","Cabotegravir","Rilpivirine","AIDS",[121,122,119,123,124],"cabotegravir","rilpivirine","quality of life","viral control","2025-08-17",{"date":127,"type":38},"2025-08-20",{"date":129,"type":22},"2025-08-15",{"date":73,"type":22},{"name":44,"class":45},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":112,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":75},"100583945","applications-of-ultrasound-and-physical-parameters-in-assessing-fall-risk-in-patients-with-knee-osteoarthritis-100583945","NCT06882928","Applications of Ultrasound and Physical Parameters in Assessing Fall Risk in Patients With Knee Osteoarthritis","Applications of Ultrasound and Physical Parameters in Assessing Fall Risk Among Patients With Knee Osteoarthritis: A Prospective Cohort Study","UPPFR-KneeOA","Inclusion Criteria:\n\n1. Males and females aged 60 and above, who are willing to sign an informed consent form.\n2. Participants must have a clinically confirmed diagnosis of knee osteoarthritis.\n3. Participants must have received at least one treatment in the outpatient rehabilitation department during the study period.\n4. Participants must be able to walk independently, even with the aid of assistive devices.\n\nExclusion Criteria:\n\n1. Individuals who have undergone lower limb surgery or have significant lower limb deformities.\n2. Individuals with severe cognitive impairment who are unable to understand or comply with the study procedures.\n3. Individuals who cannot communicate in a language understandable by the research team.\n4. Individuals with severe comorbidities that affect assessment or treatment (e.g., unable to safely complete assessments or treatments).\n5. Individuals planning to undergo knee surgery during the study period.","60 Years",{"count":142,"type":22},250,"3 Months","Falls are a significant issue for patients with knee osteoarthritis, as they can lead to hospitalization or even more severe consequences. Therefore, it is crucial to assess fall risk early in rehabilitation clinics. Sarcopenia, which is the reduction of muscle mass, increases the risk of falls. This study involved 250 adults with knee osteoarthritis, using a technology called POCUS to assess muscle mass, combined with other tests to track fall incidents over three months. The study is expected to find correlations between falls and factors like muscle mass and grip strength. This information can help doctors better predict which patients are at risk of falling and take preventive measures early. Future research will explore the effectiveness of different prevention strategies.",[146,147,148,149],"Knee Osteoarthritis","Ultrasound Exams","Fall Risk","Sarcopenia in Elderly","2025-03-18",{"date":152,"type":38},"2025-03-19",{"date":154,"type":22},"2025-03-24",{"date":73,"type":22},{"name":44,"class":45},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":75},"100562606","clinical-impact-of-rapid-molecular-testing-for-pathogens-in-patients-with-severe-acute-respiratory-illness--a-pragmatic-trial-100562606","NCT06605352","Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial","CIRT-RMT-SARI","Inclusion Criteria:\n\n1. Admitted to the ED\n2. Age ≥18 years old\n3. Diagnosis of SARI -modified from the World Health Organization definition:\n\n   * history of fever or measured fever of ≥ 38 C° and cough\n   * with onset within the last 10 days.\n   * requires hospitalization.\n   * with SpO2 on presentation less than 95% or respiratory rate more than 20 per minute, or requirement of intubation and mechanical ventilation.\n\nExclusion Criteria:\n\n1. Patients receiving palliative care\n2. Patients who declined sample collection\n3. Patients fail to provide written informed consent.\n4. Patients highly suspected or diagnosed pulmonary non-infectious disease (tumor, immune disease, etc) without evidence of infection.\n5. Patients diagnosed with COVID-19 within last 3 months.\n6. HIV-infected patients.\n7. Off work hour collected samples will be excluded from the study.\n8. Patients who died or being transitioned to comfort care within 48 hours of enrollment.\n\nStudy Population Description Inclusion criteria will be 1) ED patients age 18 or older; 2) presenting to the emergency department with acute severe respiratory illness. We define a case of severe acute respiratory illness (SARI) according to a previously suggested WHO case definition for all adults in whom onset of illness occurred within 7 days of admission. We defined SARI in adult as physician-diagnosed lower respiratory tract infection (LRTI) with SpO2 on presentation less than 95% or respiratory rate more than 20 per minute, or requirement of intubation and mechanical ventilation.\n\nSampling Method: random sampling",{"count":165,"type":22},800,[25],"Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy. Due to the indistinguishable clinical symptoms between viral and bacterial pathogens, patients with viral respiratory infection are usually under-evaluated while unnecessary antibacterial agents are more likely to be administered. With the development of highly sensitive end-to-end point-of-care (POC) multiplex PCR system, rapid diagnosis of respiratory pathogens for CAP in the ED becomes possible. Our previous NTUH-VGH cooperative research project demonstrated POC respiratory viral testing' in conjunction with procalcitonin test can reduce the length of hospital stay and antibiotic consumption. However, viral testing alone cannot guide precision antimicrobial treatment. A complete pneumonia pathogen testing panel should include bacteria, virus, atypical pathogens, and resistant genes. In addition, such test need to be completed within about time at a reasonable cost. The difficult missing has been recently achieved. The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18 bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes. Currently, the world is eagerly to learn how this new diagnostic technology can transform the clinical management of pneumonia. With this in mind, the aim of this study is to evaluate the impact of POC pneumonia pathognome wide testing on the antimicrobial use and outcome of patients. We will perform an open label pragmatic parallel comparison between patients with\u002Fwithout the test. The results will inform the pneumonia guideline. Subsequent health economic analysis based on this study will be important to the reimbursement policy of the health insurance of Taiwan.",[169,170],"Community-Acquired Pneumonia (CAP)","Pneumonia",[172,173,174,170,175,176],"Community-acquired pneumonia (CAP)","multiplex PCR","emergency department (ED)","Procalcitonin(PCT)","antimicrobial resistance","2024-09-18",{"date":179,"type":38},"2024-09-20",{"date":179,"type":22},{"date":182,"type":22},"2026-12",{"name":44,"class":45},""]